Dent Neurosciences Research Center

Running trials

• Enrolling by invitation

  Long-term Safety and Tolerability of BHV-7000

  NCT06443463· Phase 2· Source

• Active, not recruiting

  Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06309966· Phase 2/3· Source

• Active, not recruiting

  A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

  NCT06132893· Phase 2/3· Source

• Recruiting

  Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

  NCT04743141· Phase 3· Source

• Recruiting

  Randomized Study in Children and Adolescents With Migraine: Acute Treatment

  NCT04649242· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

  NCT03796962· Phase 2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Migraine2 recruiting
• Epilepsy1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Study of K-645 in the Treatment of Multiple Migraine Attacks

  NCT07116499· Phase 2· Source

• Completed

  A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine

  NCT06848075· Phase 2· Source

• Completed

  A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

  NCT06701526· Phase 4· Source

• Completed

  Study to Evaluate 5-ALA Combined With CV01 Delivery of Ultrasound in Recurrent High Grade Glioma

  NCT05362409· Phase 1· Source

• Recruiting

  A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

  NCT05164172· Phase 3· Source

• Recruiting

  A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

  NCT04965675· Phase 3· Source

• Completed

  Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

  NCT03832998· Phase 3· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· Source